These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

578 related articles for article (PubMed ID: 29172780)

  • 41. Modern mucosal vaccines, adjuvants and microbicides.
    Cranage MP; Manoussaka M
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):21-3. PubMed ID: 19622054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccine adjuvant technology: from mechanistic concepts to practical applications.
    Degen WG; Jansen T; Schijns VE
    Expert Rev Vaccines; 2003 Apr; 2(2):327-35. PubMed ID: 12899582
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Montanide ISA™ 201 adjuvanted FMD vaccine induces improved immune responses and protection in cattle.
    Dar P; Kalaivanan R; Sied N; Mamo B; Kishore S; Suryanarayana VV; Kondabattula G
    Vaccine; 2013 Jul; 31(33):3327-32. PubMed ID: 23735678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles.
    Srivastava A; Gowda DV; Madhunapantula SV; Shinde CG; Iyer M
    APMIS; 2015 Apr; 123(4):275-88. PubMed ID: 25630573
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nanoparticle vaccines.
    Zhao L; Seth A; Wibowo N; Zhao CX; Mitter N; Yu C; Middelberg AP
    Vaccine; 2014 Jan; 32(3):327-37. PubMed ID: 24295808
    [TBL] [Abstract][Full Text] [Related]  

  • 46. "IDEAL" vaccines for resource poor settings.
    Levine MM
    Vaccine; 2011 Dec; 29 Suppl 4():D116-25. PubMed ID: 22486974
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccine adjuvants: Why and how.
    Christensen D
    Hum Vaccin Immunother; 2016 Oct; 12(10):2709-2711. PubMed ID: 27551808
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pulmonary vaccine delivery.
    Lu D; Hickey AJ
    Expert Rev Vaccines; 2007 Apr; 6(2):213-26. PubMed ID: 17408371
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel Adjuvants and Immunomodulators for Veterinary Vaccines.
    Heegaard PM; Fang Y; Jungersen G
    Methods Mol Biol; 2016; 1349():63-82. PubMed ID: 26458830
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictive markers of safety and immunogenicity of adjuvanted vaccines.
    Mastelic B; Garçon N; Del Giudice G; Golding H; Gruber M; Neels P; Fritzell B
    Biologicals; 2013 Nov; 41(6):458-68. PubMed ID: 24071553
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Recommendations and barriers to vaccination in systemic lupus erythematosus.
    Garg M; Mufti N; Palmore TN; Hasni SA
    Autoimmun Rev; 2018 Oct; 17(10):990-1001. PubMed ID: 30103044
    [TBL] [Abstract][Full Text] [Related]  

  • 52. From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease.
    Mortellaro A; Ricciardi-Castagnoli P
    Immunol Cell Biol; 2011 Mar; 89(3):332-9. PubMed ID: 21301476
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjuvants and delivery issues related to immunization: a survey of the recent patent literature.
    Mrsny RJ
    J Drug Target; 1998; 6(4):243-9. PubMed ID: 9894692
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Examination of the effects of virus inactivation methods on the induction of antibody- and cell-mediated immune responses against whole inactivated H9N2 avian influenza virus vaccines in chickens.
    Astill J; Alkie T; Yitbarek A; Taha-Abdelaziz K; Bavananthasivam J; Nagy É; Petrik JJ; Sharif S
    Vaccine; 2018 Jun; 36(27):3908-3916. PubMed ID: 29853199
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of nanoparticle adjuvants to potentiate the immune response against diphtheria toxoid.
    Alshanqiti FM; Al-Masaudi SB; Al-Hejin AM; El-Baky NA; Redwan EM
    Hum Antibodies; 2018 Feb; 26(2):75-85. PubMed ID: 29171990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Controlled delivery of antigens and adjuvants in vaccine development.
    Zhao Z; Leong KW
    J Pharm Sci; 1996 Dec; 85(12):1261-70. PubMed ID: 8961136
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A strategic approach to vaccine development: animal models, monitoring vaccine efficacy, formulation and delivery.
    Griffin JF
    Adv Drug Deliv Rev; 2002 Oct; 54(6):851-61. PubMed ID: 12363434
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antigen delivery systems and immunostimulation.
    Schijns VE
    Vet Immunol Immunopathol; 2002 Sep; 87(3-4):195-8. PubMed ID: 12072234
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Liposomal vaccine delivery systems.
    Henriksen-Lacey M; Korsholm KS; Andersen P; Perrie Y; Christensen D
    Expert Opin Drug Deliv; 2011 Apr; 8(4):505-19. PubMed ID: 21413904
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New developments in nanoparticle-based vaccination.
    Riedmann EM
    Hum Vaccin Immunother; 2013 Dec; 9(12):2502. PubMed ID: 24716209
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.